USA - NASDAQ:XENE - CA98420N1050 - Common Stock
Taking everything into account, XENE scores 3 out of 10 in our fundamental rating. XENE was compared to 534 industry peers in the Biotechnology industry. While XENE has a great health rating, there are worries on its profitability. XENE is valued expensive and it does not seem to be growing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.26% | ||
| ROE | -43.89% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 46.09 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 15.14 | ||
| Quick Ratio | 15.14 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
41.92
-0.75 (-1.76%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 430.99 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.1 | ||
| P/tB | 5.1 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -41.26% | ||
| ROE | -43.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 60.66% | ||
| Cap/Sales | 20.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 15.14 | ||
| Quick Ratio | 15.14 | ||
| Altman-Z | 46.09 | 
ChartMill assigns a fundamental rating of 3 / 10 to XENE.
ChartMill assigns a valuation rating of 0 / 10 to XENON PHARMACEUTICALS INC (XENE). This can be considered as Overvalued.
XENON PHARMACEUTICALS INC (XENE) has a profitability rating of 1 / 10.
The Earnings per Share (EPS) of XENON PHARMACEUTICALS INC (XENE) is expected to decline by -43.44% in the next year.